Generic Name and Formulations:
Timolol (as hemihydrate) 0.25%, 0.5%; oph. soln; contains benzalkonium chloride.
Indications for BETIMOL:
1 drop twice daily.
Overt heart failure. Cardiogenic shock. Sinus bradycardia. 2nd- or 3rd-degree AV block. Asthma. Severe COPD.
Discontinue if heart failure develops and prior to surgery. Not for use as sole agent in narrow-angle glaucoma. Avoid abrupt cessation. Cerebrovascular insufficiency. Diabetes. COPD. Bronchospastic disease. May mask signs of hypoglycemia, thyrotoxicosis. Myasthenia gravis. Bacterial keratitis. Measure IOP after 4 wks of treatment. Pregnancy (Cat.C). Nursing mothers: not recommended.
May potentiate systemic β-blockers, reserpine. May cause conduction defects with calcium channel blockers, digitalis. May antagonize β-agonists. May block epinephrine.
Ocular irritation, eyelid erythema, conjunctival injection, headache, epiphora, photophobia. Systemic β-blocking effects (bradycardia, arrhythmias, hypotension, bronchospasm, heart failure).
Soln—5mL, 10mL, 15mL
Neurology Advisor Articles
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL
- Congress Passes Bill to Fight Opioid Crisis
- Pediatric Migraine: Evidence-Based Alternative Management
- Review of Factors Impacting Sport-Related Concussion Headaches